Overview

Since its foundation in 2005, the Apogenix team has built a promising product pipeline with currently two product candidates having a huge potential for the treatment of various diseases. Main focus is on the development of novel cancer treatments.
The CD95L blocker APG101 is currently in clinical development for GBM and MDS. In addition, inhibition of the CD95L offers a novel treatment option for solid tumours beyond GBM. Apogenix owns an extensive patent portfolio covering APG101 at least until 2024. Furthermore, the company has been granted „orphan drug“ designations in US and Europe for the treatment of glioma and glioblastoma, respectively. The product is manufactured in an efficient GMP process well-suited for the production of clinical phase III material and market supply. Apogenix is the owner of this production process.
TRAIL receptor agonists such as, e.g., APG350, will be developed for the treatment of solid tumours. The novel mode of action of these compounds is protected by a series of patent applications filed by Apogenix in the last years. Apogenix´ TRAIL receptor agonists can be produced with excellent yields at laboratory scale. It is planned to initiate the development of a GMP cell line in 2012.